Abstract
Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced for the treatment of AIDS. The molecular designing is the first stage in production of Fc-fusion proteins. The amino acid residues in the Fc region and linked protein are very important in the bioactivity and affinity of the fusion proteins. Although, therapeutic monoclonal antibodies are the top selling biologics but the application of therapeutic Fc-fusion proteins in clinic is in progress and among these medications Etanercept is the most effective in therapy. At present, eleven Fc-fusion proteins have been approved by FDA. There are novel Fc-fusion proteins which are in pre-clinical and clinical development. In this article, we review the molecular and biological characteristics of Fc-fusion proteins and then further discuss the features of novel therapeutic Fc-fusion proteins.
Keywords: Fc-fusion proteins, immunotherapy, FcRn, antibody, Fc region.
Current Medicinal Chemistry
Title:Fc-fusion Proteins in Therapy: An Updated View
Volume: 24 Issue: 12
Author(s): Reza Jafari, Naime M. Zolbanin, Houshang Rafatpanah, Jafar Majidi and Tohid Kazemi*
Affiliation:
- Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, P.O. Box: 5165683146, Tabriz,Iran
Keywords: Fc-fusion proteins, immunotherapy, FcRn, antibody, Fc region.
Abstract: Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced for the treatment of AIDS. The molecular designing is the first stage in production of Fc-fusion proteins. The amino acid residues in the Fc region and linked protein are very important in the bioactivity and affinity of the fusion proteins. Although, therapeutic monoclonal antibodies are the top selling biologics but the application of therapeutic Fc-fusion proteins in clinic is in progress and among these medications Etanercept is the most effective in therapy. At present, eleven Fc-fusion proteins have been approved by FDA. There are novel Fc-fusion proteins which are in pre-clinical and clinical development. In this article, we review the molecular and biological characteristics of Fc-fusion proteins and then further discuss the features of novel therapeutic Fc-fusion proteins.
Export Options
About this article
Cite this article as:
Jafari Reza, Zolbanin M. Naime, Rafatpanah Houshang, Majidi Jafar and Kazemi Tohid*, Fc-fusion Proteins in Therapy: An Updated View, Current Medicinal Chemistry 2017; 24 (12) . https://dx.doi.org/10.2174/0929867324666170113112759
DOI https://dx.doi.org/10.2174/0929867324666170113112759 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Defensin Participation in Innate and Adaptive Immunity
Current Pharmaceutical Design Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cancer Therapy Reviews Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging Advances in Electrospinning of Nanofibers and their Biomedical Applications
Current Tissue Engineering (Discontinued) Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Polymer Membrane and Cell Models for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry Isolation of a New Trypsin Inhibitor from the Faba Bean (Vicia faba cv. Giza 843) with Potential Medicinal Applications
Protein & Peptide Letters The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function
Current Medicinal Chemistry